MANUSCRIPT # ERJ-00078-2006 - REVISION #1

EFFECT OF SMOKING CESSATION ON COUGH REFLEX SENSITIVITY

Peter V. Dicpinigaitis¹, Brigita Sitkauskiene², Kristina Stravinskaite², David W. Appel¹, Abdissa Negassa¹, Raimundas Sakalauskas²

¹Albert Einstein College of Medicine and Montefiore Medical Center, Bronx, NY, USA; ²Kaunas University of Medicine, Kaunas, Lithuania

Short title: Smoking cessation and cough sensitivity

Presented in part at the European Respiratory Society Annual Congress, Copenhagen, Denmark, Sept. 20, 2005

Correspondence and reprints:

Peter V. Dicpinigaitis, MD Einstein Division/Montefiore Medical Center 1825 Eastchester Road Bronx, NY 10461 USA Tel (718) 904-2676 Fax (718) 904-2880

e-mail: pdicpinigaitis@pol.net

Abstract

Recent studies have shown that cigarette smokers have diminished cough reflex sensitivity compared to nonsmokers. We proposed a mechanism of chronic cigarette smoke-induced desensitization of airway cough receptors.

To r investigate this hypothesis, we measured cough sensitivity to inhaled capsaicin (C_5) in chronic smokers while they were actively smoking and 2, 6, 12 and 24 weeks after smoking cessation.

Twenty-nine subjects underwent baseline capsaicin challenge while smoking and two weeks after smoking cessation. Mean (\pm SEM) log C₅ fell from 1.86 \pm 0.12 to 1.60 \pm 0.12 (p=0.0004), demonstrating significant enhancement of cough reflex sensitivity. Twenty, 18, and 14 subjects successfully abstained from smoking for 6, 12 and 24 weeks, respectively. Mean log C₅ after 12 and 24 weeks of smoking cessation were significantly diminished from baseline (p=0.03 and p=0.008, respectively). In a control group of smokers, mean log C₅ did not decrease from baseline after 6, 12 and 24 weeks. Overall, the log C₅ profile of the smoking cessation group showed a clear, linearly-decreasing trend over time compared to the control group (p=0.0001).

Even after many years of smoking, cough sensitivity is enhanced as early as two weeks after smoking cessation. Given the importance of an intact cough reflex, these changes may provide clinical benefit.

Key words: capsaicin, cigarette smoking, cough, nicotine, tobacco

Introduction

Cough results from the stimulation of airway sensory receptors whose afferent impulses activate a brainstem cough center [1]. The cough reflex serves a protective function by facilitating the expulsion of mucus from the respiratory tract and by preventing foreign material from entering the airways.

We and others have recently shown that healthy cigarette smokers have diminished cough reflex sensitivity compared to healthy nonsmokers [2,3]. We hypothesized that chronic exposure to tobacco smoke desensitizes the cough receptors lying superficially within the airway epithelium. Supporting our speculation is the demonstrated lower incidence of angiotensin-converting enzyme inhibitor-induced cough in smokers relative to nonsmokers [4,5], and anecdotal observations that cough often transiently increases after smoking cessation [6].

Alternatively, it has been proposed that diminished cough reflex sensitivity in smokers is not due to the effects of tobacco use, but rather that cigarette smokers comprise a select group of individuals with naturally diminished cough reflex sensitivity that allows them to tolerate and enjoy smoking [2,7,8]. In support of this hypothesis were multiple small studies that demonstrated decreased cough reflex sensitivity in persons who enjoyed occasional smoking, compared to regular smokers and nonsmokers [9-11].

To further explore the mechanism of diminished cough reflex sensitivity in cigarette smokers, we performed the present study evaluating the effect of smoking cessation on the sensitivity of the cough reflex.

Methods

Subjects

Healthy, active smokers who were planning smoking cessation were recruited for the study, which was approved by the Institutional Review Boards of both study sites:

Montefiore Medical Center, New York, and Kaunas University of Medicine, Kaunas,
Lithuania. A smoker was arbitrarily defined as an individual who had smoked at least 5
cigarettes daily for at least one year. Subjects were without history of pulmonary disease,
or recent (within 4 weeks) symptoms suggestive of respiratory tract infection or seasonal
allergies. Subjects were not receiving any medication known to affect cough reflex
sensitivity.

Upon enrollment, subjects underwent initial capsaicin cough challenge testing while still actively smoking, to determine their baseline cough reflex sensitivity. Subjects then discontinued smoking, at a time of their determination. Subjects were allowed to use pharmacological smoking cessation aids, including nicotine replacement (transdermal patches and chewing gum) and bupropion, at their discretion and that of their physicians.

Ten healthy smokers, fulfilling the aforementioned criteria, were recruited to serve as a control group.

Capsaicin Cough Challenge

Subjects underwent capsaicin cough challenge at baseline (while still actively smoking), and again 2, 6, 12 and 24 weeks after successful smoking cessation. Control subjects underwent capsaicin cough challenge at the same time intervals. Cough challenge testing was performed as previously described [12]. Briefly, solutions of capsaicin (Sigma Chemical Co., St. Louis, MO, USA) were prepared to make a stock

solution of 0.01M, and subsequently further diluted with physiologic saline solution to yield serial doubling concentrations ranging from 0.98 μ M to 1,000 μ M. Fresh dilutions were prepared on each day of testing.

Subjects inhaled single breaths (from FRC to TLC) of capsaicin aerosol administered via a nebulizer (model 646; De Vilbiss Health Care Inc.; Somerset, PA, USA) controlled by a dosimeter (KoKO Digidoser; Ferraris Respiratory, Louisville, CO, USA). The nebulizers used in this study were modified in two ways. Firstly, an inspiratory flow regulator valve (RIFR; Ferraris Respiratory) was added, which limited the inspiratory flow rate to 0.5 l/s regardless of excessive inspiratory force, thereby guaranteeing a consistent and reproducible inspiratory effort with each breath. Secondly, the straw and baffle assembly of each nebulizer was welded in place, thereby eliminating the variations in nebulizer output that occur when these components are detached for washing and then reattached with resulting variable distances between the jet orifice and the straw. Under these conditions, the output of the nebulizers used in this study was 0.02 ml/breath. Single breaths of capsaicin aerosol were administered in order of ascending concentration, with inhalations of saline randomly interspersed to increase challenge blindness, until the concentration inducing 5 or more coughs (C_5) was reached. Breaths were delivered at one-minute intervals. Subjects were unaware that the end point of the study was the number of coughs induced.

Exhaled Carbon Monoxide Measurement

Prior to each cough challenge, to confirm smoking or nonsmoking status, subjects underwent measurement of exhaled carbon monoxide (CO) using a portable breath CO monitor (Bedfont EC50 Micro Smokerlyzer, Bedfont Scientific Ltd.; Kent, UK). Previous

studies with this instrument have demonstrated that a breath CO level of 6 parts per million (ppm) serves as a cutoff value that distinguishes smoking from nonsmoking outpatients, with a sensitivity of 94% and a selectivity of 96% [13].

Data Analysis

In the smoking cessation group, differences in cough reflex sensitivity measurements at different time periods were evaluated by comparing values for mean log C_5 using a paired Student t test for dependent samples. In comparing the profile of log C_5 between the smoking cessation and active smoking groups, we employed linear mixed effects models [14] in order to use all available data and to take into account the within-subject correlation of log C_5 measurements. In all analyses, a two-tailed test was employed and p values less than 0.05 were considered to be significant.

Results

Twenty-nine subjects (18 men, 11 women) were enrolled and, after undergoing baseline cough reflex sensitivity measurement, successfully abstained from smoking for at least two weeks. Mean (±SEM) age of the subjects was 28.0±2.0 yr, (range 19-58); mean duration of smoking was 9.5±1.7 yr, (range 1.5-43); mean value for pack-years was 9.8±2.2 yr, (range 1.5-50). The time interval from baseline cough reflex sensitivity measurement while smoking until onset of smoking cessation was 5.4±1.6 days (range 1-30 days). All subjects underwent exhaled CO measurements at the time of enrollment. Twenty-six of 29 subjects had exhaled CO measurements of ≥6 ppm, supporting active smoking status [13]. The 3 subjects whose exhaled CO measurements were <6 ppm had all abstained from smoking for at least 8 hours prior to evaluation, thus likely allowing their exhaled CO levels to diminish. The range of exhaled CO values was 2-34 ppm, with a mean of 16.6±1.6 ppm. Pharmacological smoking cessation aids were used as follows (number of subjects in parentheses): nicotine patch and nicotine gum (7); nicotine patch alone (4); nicotine gum alone (4); nicotine gum and bupropion (1); nicotine patch and clonidine patch (1); nicotine patch, clonidine patch and bupropion (1); no pharmacological smoking cessation aids (11).

After two weeks of smoking cessation, there was a significant enhancement of cough reflex sensitivity, i.e., decrease in C_5 . Mean (\pm SEM) log C_5 fell from a baseline of 1.86 ± 0.12 to 1.60 ± 0.12 (p=0.0004) [Figure 1]. One doubling-concentration change in C_5 is represented by a 0.3 unit change in log C_5 . Twenty-seven of the 29 subjects demonstrated exhaled CO levels of \leq 6 ppm, confirming their nonsmoking status. In two

subjects, exhaled CO measurements were not performed due to malfunction of the instrument.

After 6 weeks, 9 subjects had resumed smoking. Of the 20 subjects remaining, mean $\log C_5$ after 6 weeks of smoking cessation was less than that after two weeks of smoking cessation, but the difference did not reach statistical significance (Figure 2). In this group of subjects, as in the entire group, there was a significant decrement in mean $\log C_5$ after two weeks of smoking cessation (p=0.01) [Figure 2]. Exhaled CO measurements demonstrated 16 of 18 subjects to have levels of \leq 6 ppm; two subjects had levels of 7 ppm. In two subjects, measurements were not performed due to malfunction of the instrument.

After 12 weeks, 18 subjects continued to abstain from smoking. In these subjects, mean $\log C_5$ continued to fall after each time interval, but the differences between consecutive measurements did not reach statistical significance. Mean $\log C_5$ after 12 weeks of smoking cessation was significantly lower than baseline (p=0.03) [Figure 2]. Of these subjects, 15 underwent exhaled CO measurement; 14 demonstrated an exhaled CO level of \leq 6 ppm, and one subject had a level of 7 ppm. Three subjects did not undergo exhaled CO measurement due to malfunction of the instrument.

By the end of the 24-week study period, 14 of the original 29 subjects had continued to abstain from smoking. In this group, mean $\log C_5$ continued to decrease at each study interval, though differences between consecutive measurements did not reach statistical significance . Mean $\log C_5$ after 24 weeks of smoking cessation was significantly lower compared with baseline (p=0.008) [Figure 2]. Exhaled CO measurements were ≤ 6 ppm in 13 of the 14 subjects; in one subject, the level was 7 ppm.

Ten control subjects (7 men, 3 women) continued to smoke throughout the 24-week study period. For the control group, mean (\pm SEM) age was 28.5 \pm 1.7 yr; mean duration of smoking was 9.4 \pm 1.9 yr; and mean value for pack-years was 6.9 \pm 1.8 yr. There was a small decrement in mean log C_5 after two weeks that did not reach statistical significance (p=0.64). The mean log C_5 levels after 6, 12 and 24 weeks were higher than baseline, in contrast to the smoking cessation group . The profile of log C_5 by smoking status is presented in Figure 2. Using a linear mixed effects model, the difference in the profile of log C_5 between the smoking cessation and active smoking (control) groups was statistically significant, i.e., the log C_5 profile of the smoking cessation group showed a clear, linearly-decreasing trend over time as compared to the control group (p=0.0001).

Discussion

We have previously shown that healthy cigarette smokers have a diminished cough reflex sensitivity relative to nonsmokers [2]. We speculated that the suppression of the cough reflex was due to chronic cigarette smoke-induced desensitization of airway cough receptors [2]. To further investigate these findings, we performed the present study that evaluated the effect of smoking cessation on cough reflex sensitivity in subjects who had been chronic smokers. Our results demonstrate that even after many years of cigarette smoking, cough reflex sensitivity is measurably enhanced as early as two weeks after smoking cessation. In some subjects, further enhancement of cough reflex sensitivity continued 6, 12 and 24 weeks after smoking cessation; however, the major effect appears to have occurred within the initial two weeks after discontinuation of smoking.

The results of this study support our hypothesis that chronic exposure to cigarette smoke desensitizes afferent cough receptors within the airway epithelium [2], since removal of this noxious stimulus allowed the demonstration of increased cough reflex sensitivity. Presumably, rapidly-adapting pulmonary stretch receptors (RARs) and/or C fibers, receptors believed to be involved in the cough reflex [1], are desensitized, albeit reversibly, by regular and prolonged exposure to cigarette smoke. Changes in airway mucus secretion may be relevant to our observations as well. If, for example, mucus secretion decreased after smoking cessation, a thinner mucus layer may have rendered the airway cough receptors less shielded from the tussive agent capsaicin during the post-smoking cessation cough challenge study.

Our data also show that the cough reflex is quite dynamic, since changes in sensitivity to capsaicin were demonstrable as early as two weeks after many years, in some cases, of cigarette smoking. Furthermore, these results contradict the alternate hypothesis that cigarette smokers comprise a group of individuals with naturally-occurring diminished cough reflex sensitivity that renders them able to tolerate and enjoy cigarette smoking [7,8].

Multiple studies have demonstrated that cough reflex sensitivity measurements with inhaled capsaicin are highly reproducible, both in the short and long term[12]. However, there is great interindividual variation in cough reflex sensitivity among healthy individuals [12]. Thus, the observation that the mean $\log C_5$ in our control group of active smokers increased during the course of the study was unexpected. We attribute this to a chance result (or random variation) given the small size (n=10) of the group. Nevertheless, the controls served as a clear contrast to the smoking cessation group, whose mean $\log C_5$ steadily decreased, indicating enhancement of cough reflex sensitivity, throughout the duration of the study.

We feel that it is unlikely that the pharmacological smoking cessation aids used by some of our subjects affected our data in any significant way. For example, when we separated our subjects into those that did and did not use drugs (mainly nicotine replacement) to aid smoking cessation, the majority of subjects in each group demonstrated an enhancement of cough reflex sensitivity two weeks after discontinuation of smoking. Furthermore, previous studies have shown that inhaled nicotine induces cough in healthy subjects [15]. Therefore, if nicotine were a significant contributor to the

degree of cough reflex sensitivity in smokers, one would expect a diminution of cough reflex sensitivity after smoking cessation, whereas we observed the opposite effect.

Another relevant question to consider is the possibility that transdermal nicotine patches could have produced blood levels of nicotine in our subjects higher than those present during active smoking. If that were the case and, if nicotine indeed potentiated the cough reflex [15], then such an effect could have contributed to our observation of enhanced cough reflex sensitivity after smoking cessation. However, previous studies comparing blood nicotine levels during active smoking and after smoking cessation while using transdermal nicotine replacement have demonstrated lower or similar nicotine levels with the nicotine patch [16-18]. Only a high-dose nicotine patch (44 mg) has been shown to achieve similar or higher blood nicotine levels compared to the active smoking period [17,19]. Our study subjects used patches of 21 mg or less. Thus, higher blood nicotine levels in our post-smoking cessation subjects are highly unlikely to have contributed to our observed results. Lastly, clonidine has been shown to have no effect on capsaicin-induced cough in humans [20].

The suppression of the cough reflex, an important respiratory defense mechanism, may have significant clinical ramifications in smokers. Tobacco smoke-induced inhibition of the cough reflex may contribute to the significantly increased risk of bacterial and viral respiratory tract infections in cigarette smokers [21]. A diminished cough reflex has been associated with an increased risk of developing aspiration pneumonia in stroke patients [22] and in the elderly [23]. Conversely, hypertensive stroke patients treated with angiotensin-converting enzyme inhibitors, agents that enhance cough reflex sensitivity, have a lower incidence of pneumonia compared with stroke

patients treated with other classes of antihypertensive drugs [24,25]]. Furthermore, studies using radiolabeled aerosols have shown that young, healthy smokers with normal pulmonary function are unable to enhance their rate of mucus clearance by coughing, suggesting an alteration in the mucociliary apparatus [26].

Given the importance of an intact cough reflex as a vital respiratory defense mechanism, the results of this study, demonstrating the reversal of chronic, cigarette smoke-induced suppression of cough reflex sensitivity after smoking cessation, offer yet another reason for smokers to discontinue the use of tobacco.

References

- Widdicombe JG. Neurophysiology of the cough reflex. Eur Respir J 1995;8:1193-1202.
- 2 Dicpinigaitis PV. Cough reflex sensitivity in cigarette smokers. Chest 2003;123:685-688.
- 3 Millqvist E, Bende M. Capsaicin cough sensitivity is decreased in smokers.

 Respir Med 2001;95:19-21.
- 4 Strocchi E, Malini PL, Valtancoli G, Ricci C, Bassein L, Ambrosioni E. Cough during treatment with angiotensin converting enzyme inhibitors: analysis of predisposing factors. Drug Investig 1992;4:69-72.
- Israili ZH, Hall WD. Cough and angioneurotic edema associated with angiotensin-converting enzyme inhibitor therapy. Ann Intern Med 1992;117:234-242.
- 6 Cummings KM, Giovino G, Jaen CR, Emrich LJ. Reports of smoking withdrawal symptoms over a 21-day period of abstinence. Addict Behav 1985;10:373-381.
- 7 Lalloo UG. The cough reflex and the "healthy smoker." Chest 2003;123:660-662.
- 8 Ebihara S, Ebihara T, Okazaki T, Sasaki H. Cigarette smoking, cough reflex, and respiratory tract infection [letter]. Arch Intern Med 2005;165:814.
- 9 Schmidt D, Jorres RA, Magnussen H. Citric acid-induced cough thresholds in normal subjects, patients with bronchial asthma, and smokers. Eur J Med Res 1997;2:384-388.

- Pounsford JC, Saunders KB. Cough response to citric acid aerosol in occasional smokers. Br Med J 1986;293:1528.
- Vlastos FD, Desanges JF, Lockhart A, Pretet S. Cough and bronchial obstruction induced by citric acid in smokers, occasional smokers, and nonsmokers (French). Rev Mal Respir 1991;8:397-401.
- Dicpinigaitis PV. Short- and long-term reproducibility of capsaicin cough challenge testing. Pulm Pharmacol Ther 2003;16:61-65.
- 13 Middleton ET, Morice AH. Breath carbon monoxide as an indication of smoking habit. Chest 2000;117:758-763.
- Laird NM, Ware JH. Random-effects models for longitudinal data. Biometrics 1982;38:963-974.
- Hansson L, Choudry NB, Karlsson J-A, Fuller RW. Inhaled nicotine in humans: effect on the respiratory and cardiovascular systems. J Appl Physiol 1994;76:2420-2427.
- Hurt RD, Dale LC, Offord KP, Lauger GG, Baskin LB, Lawson GM, et al.
 Serum nicotine and cotinine levels during nicotine-patch therapy. Clin
 Pharmacol Ther 1993;54:98-106.
- Lawson GM, Hurt RD, Dale LC, Offord KP, Croghan IT, Schroeder DR, et al.

 Application of serum nicotine and plasma cotinine concentrations to
 assessment of nicotine replacement in light, moderate, and heavy smokers
 undergoing transdermal therapy. J Clin Pharmacol 1998;38:502-509.

- Ogburn PL, Hurt RD, Croghan IT, Schroeder DR, Ramin KD, Offord KP, et al. Nicotine patch use in pregnant smokers: nicotine and cotinine levels and fetal effects. Am J Obstet Gynecol 1999;181:736-743.
- 19 Fredrickson PA, Hurt RD, Lee GM, Wingender L, Croghan IT, Lauger G, et al. High dose transdermal nicotine therapy for heavy smokers: safety, tolerability and measurement of nicotine and cotinine levels.


 Psychopharmacology 1995;122:215-222.
- O'Connell F, Thomas VE, Fuller RW, Pride NB, Karlsson J-A. Effect of clonidine on induced cough and bronchoconstriction in guinea pigs and healthy humans. J Appl Physiol 1994;76:1082-1087.
- 21 Arcavil L, Benowitz NL. Cigarette smoking and infection. Arch Intern Med 2004;164:2206-2216.
- Addington WR, Stephens RE, Gilliland K, Rodriguez M. Assessing the laryngeal cough reflex and the risk of developing pneumonia after stroke.

 Arch Phys Med Rehabil 1999;80:150-154.
- Sekizawa K, Ujiie Y, Itabashi S, Sasaki H, Takishima T. Lack of cough reflex in aspiration pneumonia [letter]. Lancet 1990;335:1228-1229.
- Sekizawa K, Matsui T, Nakagawa T, Nakayama K, Sasaki H. ACE inhibitors and pneumonia [letter]. Lancet 1998;352:1069.
- Ohkubo T, Chapman N, Neal B, Woodward M, Omae T, Chalmers J. Effects of an angiotensin-converting enzyme inhibitor-based regimen on pneumonia risk. Am J Respir Crit Care Med 2004;169:1041-1045.

Bennett WD, Chapman WF, Gerrity TR. Ineffectiveness of cough for enhancing mucus clearance in asymptomatic smokers. Chest 1992;102:412-416.

<u>Legend – Figure 1</u>

Change in cough reflex sensitivity after smoking cessation. Baseline measurement reflects cough sensitivity to capsaicin (log C_5) while subjects (n=29) were actively smoking. Two weeks after smoking cessation, mean (\pm SEM) log C_5 decreased from 1.86 ± 0.12 to 1.60 ± 0.12 (p=0.0004).



<u>Legend – Figure 2</u>

Cough reflex sensitivity(log C₅) in subjects at baseline; at 2, 6, 12 and 24 weeks after smoking cessation(open circles); and in control group of active smokers (solid circles). Data reported as mean-SEM for smoking cessation group, and mean+SEM for

control group. For control group, n=10 for all time points. For smoking cessation group, n=29 at baseline and at 2 weeks; n=20 at 6 weeks; n=18 at 12 weeks; and n=14 at 24 weeks. Attrition in smoking cessation group occurred due to resumption of smoking in some subjects.

